1. Scrip
  2. >>Focus On Asia
  3. >>China

China Cancer Drug Misuse In Spotlight After Shocking Whistleblower Tales

Guideline Non-Compliance, Off-Label Use

 
• By Brian Yang

Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.

Fllow Guidelines_1200
MISUSE OF CANCER DRUGS PREVALENT IN CHINA, PHYSICIAN ALLEGES • Source: Shutterstock

Citing widespread and overly aggressive medical practice in treating patients, and physicians' imprudent decisions, a prominent oncologist in China has openly criticized a lack of oversight, non-compliance with well-established guidelines and the misuse of cancer drugs in pursuit of personal financial gain.

In a widely circulated open letter, Zhang Yi, a specialist at the Clinical Oncology department of Beijing's Peking University No

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.